// App-Quantinova.ai

TPS11620 : Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSe Program.

Researchers

Presenter

  • Jean-Yves Blay

Principal Investigators

  • Claire Cropet

  • Julien Mazieres

  • Frederique Nowak

  • Ivan Bieche

  • Xavier Troussard

  • Etienne Lonchamp

  • Julie Charles

  • Stephane Dalle

  • Eve Maubec

  • Sophie Leboulleux

  • David Malka

  • Bertrand Arnulf

  • Aude Flechon

  • Isabelle Ray Coquard

  • David Perol

  • Veronica Pezzella

  • Marta Jimenez

  • Agnes Buzyn

Medical Centers

  • Centre Leon Berard, Lyon, France

  • French National Cancer Institute (INCa), Boulogne-Billancourt, France

  • Centre Leon Berard, Unite de Biostatistique et d'Evaluation des Therapeutiques, Lyon, France

  • Hopital Larrey Centre Hospitalier Universitaire Toulouse, Toulouse, France

  • Institut Curie, Paris Cedex, France

  • CHU Cote de Nacre, Department of Hematology, Caen, France

  • Institut National du Cancer, Boulogne Billancourt, France

  • GHM Grenoble, Grenoble, France

  • Hospices Civils De Lyon, Cancer Research Center of Lyon, Claude Bernard University Lyon, Pierre Benite, France

  • Hopital Bichat, Paris, France

  • Institut Gustave-Roussy, Villejuif, France

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Hospital Saint Antoine, Paris, France

  • UNICANCER, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Hairy cell leukemia

  • Advanced biliary tract carcinoma

  • Multiple Myeloma

  • Unspecified Cancer

  • Solid malignancies

  • Skin carcinoma

  • Sarcoma

  • Gastrointestinal stromal tumor

Biomarkers

  • N/A

Drug/Treatment

  • Vemurafenib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02304809

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved